Europeanhhm
BD - Earth day 2024

FEops Granted FDA Clearance for AI-Powered Anatomical Analysis Capabilities

Saturday, July 01, 2023

FEops has recently unveiled the latest version of its software, FEops HEARTguide™, which introduces an AI-powered anatomical analysis of MSCT images. This advancement revolutionizes the pre-operative planning for structural heart interventions by eliminating the manual measurement step. As a result, physicians can now streamline their workflow, saving valuable time. It's important to note that this AI-based analysis is not a "black box" solution. FEops still provides physicians with the option to conduct the analysis themselves. The enhanced capabilities of this release, combined with the robust clinical evidence from the PREDICT-LAA study, empower physicians with improved time efficiency and well-informed clinical decision-making for structural heart interventions.

FEops sets itself apart by offering more than just anatomical analysis through its innovative predictive simulations. These simulations provide valuable insights into how specific transcatheter structural heart devices will interact with a patient's anatomy before the actual implantation. This advanced feature enables physicians to make informed decisions regarding the optimal device size and position, leading to improved procedural efficiency and better patient outcomes.

According to Peter Mortier, PhD, co-founder and CTO of FEops, the combination of predictive simulation and AI-based anatomical analysis puts the company at the forefront of the market. This extension of their FEops HEARTguide™ software streamlines the workflow for heart teams by providing a fast, semi-automated, and accurate anatomical analysis that supports efficient and standardized planning.

Dr. Ian Buysschaert, from St Jan in Bruges, Belgium, recognizes the clinical value of FEops HEARTguide™ and its AI-based anatomical analysis. He highlights the positive impact of the software on the decision-making process for left atrial appendage occlusion (LAAO) interventions, emphasizing the simulation options that predict different device sizes and positions. The new DICOM interface further enhances the software's capabilities by allowing physicians to visualize and modify anatomical measurements, providing valuable flexibility for operators.

Matthieu De Beule, PhD, co-founder and CEO of FEops, expresses confidence in the company's ability to establish a new standard in personalized treatment planning for structural heart interventions. With a global presence, having treated over 7,000 patients in 327 hospitals across 28 countries, FEops is well-prepared for global commercialization. Leveraging their expertise in AI, regulatory affairs, physician networks, and clinical experience, FEops aims to expand their cloud-based platform beyond structural heart interventions. This strategic expansion opens up opportunities for transformative predictive digital twin applications in various fields, with an upcoming Series C round playing a pivotal role in driving these advancements.

https://www.businesswire.com/news/home/20230630173821/en/


 

The Healthcare Patient Experience & Engagement Summit 2024Healthcare Innovation & Transformation SummitHealthcare CNO SummitHealthcare CMO Summit